Cetuximab in colon cancer
1Department of Medical Oncology, National Cancer Institute, Bari - Italy.
The International Journal of Biological Markers
|February 17, 2017
Summary
New treatments for metastatic colorectal cancer include cetuximab, a targeted therapy. While effective in some patients after initial treatment, its role in first-line therapy requires further investigation.
Area of Science:
- Oncology
- Medical Research
Background:
- Metastatic colorectal cancer treatment has advanced with oxaliplatin and irinotecan.
- Biological agents, like cetuximab, are being explored to enhance chemotherapy efficacy.
Purpose of the Study:
- To evaluate the role of cetuximab in metastatic colorectal cancer treatment.
- To assess cetuximab's efficacy as a single agent and in combination therapies.
Main Methods:
- Review of clinical practice and phase II/III trials involving cetuximab.
- Analysis of cetuximab's activity in pretreated patients and first-line settings.
Main Results:
- Cetuximab shows activity in pretreated metastatic colorectal cancer patients, particularly with irinotecan.
- Phase II trials indicate promising response rates and survival benefits with cetuximab plus chemotherapy.
Conclusions:
- Cetuximab is approved for EGFR-expressing metastatic colorectal cancer post-irinotecan failure.
- Further research is needed for first-line therapy, adjuvant/neoadjuvant settings, and patient selection criteria.
